Who makes 225Ac-ABD147?

225Ac-ABD147 is developed by Abdera Therapeutics Inc..

Last reviewed 2026-04-23 · How we verify

225Ac-ABD147

Abdera Therapeutics Inc. · Phase 1 active Small molecule

At a glance

Generic name	225Ac-ABD147
Sponsor	Abdera Therapeutics Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

225Ac-ABD147 CI brief — competitive landscape report
225Ac-ABD147 updates RSS · CI watch RSS
Abdera Therapeutics Inc. portfolio CI